The role of kinin receptors in preventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Dutra, Rafael C ^a   Leite, Daniela F P ^a   Bento, Allisson F ^a   Manjavachi, Marianne N ^a   Patrício, Eliziane S ^a   Figueiredo, Cláudia P ^a   Pesquero, João B ^b   Calixto, João B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; KININ; KININ RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BRADYKININ RECEPTOR; CYTOKINE;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE DELETION; GLIA CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; C57BL MOUSE; CHRONIC DISEASE; DISEASE MODEL; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; INFLAMMATION; LYMPHOID TISSUE; METABOLISM; MYELIN SHEATH; PATHOLOGY; SPINAL CORD;

MUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE DELETION; HUMANS; INFLAMMATION; LYMPHOID TISSUE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MYELIN SHEATH; RECEPTORS, BRADYKININ; SPINAL CORD; TH1 CELLS; TH17 CELLS;

EID: 81555218160     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027875     Document Type: Article

References (55)

1. Frohman EM, Racke MK, Raine CS, (2006) Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354: 942-955.
2. McFarland HF, Martin R, (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8: 913-919.
3. Hafler DA, (2004) Multiple sclerosis. IFN-γ, TNF-α J Clin Invest 113: 788-794.
4. Kawakami N, Odoardi F, Ziemssen T, Bradl M, Ritter T, et al. (2005) Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. J Immunol 175: 69-81.
5. Goverman J, (2009) Autoimmune T cell responses in the central nervous system. Nat Rev Immunol.
6. Sospedra M, Martin R, (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747.
7. Walker K, Perkins M, Dray A, (1995) Kinins and kinin receptors in the nervous system. Neurochem Int 26: 1-16; discussion 17-26.
8. Prediger RD, Medeiros R, Pandolfo P, Duarte FS, Passos GF, et al. (2008) Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease. Neuroscience 151: 631-643.
9. Danielisova V, Gottlieb M, Nemethova M, Kravcukova P, Domorakova I, et al. (2009) Bradykinin postconditioning protects pyramidal CA1 neurons against delayed neuronal death in rat hippocampus. Cell Mol Neurobiol 29: 871-878.
10. Khan TK, Nelson TJ, Verma VA, Wender PA, Alkon DL, (2009) A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts. Neurobiol Dis 34: 332-339.
11. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, et al. (2004) Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143: 803-818.
12. Campos MM, Leal PC, Yunes RA, Calixto JB, (2006) Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol Sci 27: 646-651.
13. Prat A, Biernacki K, Saroli T, Orav JE, Guttmann CR, et al. (2005) Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol 62: 795-800.
14. Dos Santos AC, Roffe E, Arantes RM, Juliano L, Pesquero JL, et al. (2008) Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J Neuroinflammation 5: 49.
15. Gobel K, Pankratz S, Schneider-Hohendorf T, Bittner S, Schuhmann MK, et al. (2011) Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun 36: 106-114.
16. Germain L, Barabe J, Galeano C, (1988) Increased blood concentration of des-Arg9-bradykinin in experimental allergic encephalomyelitis. J Neurol Sci 83: 211-217.
17. Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, et al. (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15: 788-793.
18. Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, et al. (2000) Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol 59: 896-906.
19. Marceau F, Bachvarov DR, (1998) Kinin receptors. Clin Rev Allergy Immunol 16: 385-401.
20. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, et al. (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 15: 633-640.
21. Bjartmar C, Wujek JR, Trapp BD, (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206: 165-171.
22. Kim H, Moon C, Ahn M, Lee Y, Kim S, et al. (2007) Increased phosphorylation of cyclic AMP response element-binding protein in the spinal cord of Lewis rats with experimental autoimmune encephalomyelitis. Brain Res 1162: 113-120.
23. Gobin SJ, Montagne L, Van Zutphen M, Van Der Valk P, Van Den Elsen PJ, et al. (2001) Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 36: 68-77.
24. Kivisakk P, Imitola J, Rasmussen S, Elyaman W, Zhu B, et al. (2009) Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 65: 457-469.
25. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, et al. (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172: 146-155.
26. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, et al. (2003) Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J Neuroimmunol 141: 132-140.
27. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM, (2008) Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 14: 337-342.
28. Bettelli E, Korn T, Oukka M, Kuchroo VK, (2008) Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057.
29. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285.
30. Alvarez JI, Cayrol R, Prat A, (2011) Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 1812: 252-264.
31. Gerlai R, (2001) Gene targeting: technical confounds and potential solutions in behavioral brain research. Behav Brain Res 125: 13-21.
32. Crusio WE, Goldowitz D, Holmes A, Wolfer D, (2009) Standards for the publication of mouse mutant studies. Genes Brain Behav 8: 1-4.
33. Kiselycznyk C, Holmes A, (2011) All (C57BL/6) Mice are not Created Equal. Front Neurosci 5: 10.
34. Crusio WE, (2004) Flanking gene and genetic background problems in genetically manipulated mice. Biol Psychiatry 56: 381-385.
35. Carola V, Gross C, (2010) BDNF moderates early environmental risk factors for anxiety in mouse. Genes Brain Behav 9: 379-389.
36. Gresack JE, Risbrough VB, Scott CN, Coste S, Stenzel-Poore M, et al. (2010) Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors. Behav Brain Res 209: 80-84.
37. Mycko MP, Cwiklinska H, Walczak A, Libert C, Raine CS, et al. (2008) A heat shock protein gene (Hsp70.1) is critically involved in the generation of the immune response to myelin antigen. Eur J Immunol 38: 1999-2013.
38. Ellestad KK, Tsutsui S, Noorbakhsh F, Warren KG, Yong VW, et al. (2009) Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. J Immunol 183: 298-309.
39. Terenyi N, Nagy N, Papp K, Prechl J, Olah I, et al. (2009) Transient decomplementation of mice delays onset of experimental autoimmune encephalomyelitis and impairs MOG-specific T cell response and autoantibody production. Mol Immunol 47: 57-63.
40. Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, et al. (2003) Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J Immunol 170: 5349-5353.
41. Weiss N, Miller F, Cazaubon S, Couraud PO, (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788: 842-857.
42. Stromnes IM, Goverman JM, (2006) Active induction of experimental allergic encephalomyelitis. Nat Protoc 1: 1810-1819.
43. Zhang H, Gu YT, Xue YX, (2007) Bradykinin-induced blood-brain tumor barrier permeability increase is mediated by adenosine 5′-triphosphate-sensitive potassium channel. Brain Res 1144: 33-41.
44. Qin LJ, Gu YT, Zhang H, Xue YX, (2009) Bradykinin-induced blood-tumor barrier opening is mediated by tumor necrosis factor-alpha. Neurosci Lett 450: 172-175.
45. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, et al. (1996) Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 141: 214-224.
46. Emerich DF, Dean RL, Marsh J, Pink M, Lafreniere D, et al. (2000) Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharm Res 17: 1212-1219.
47. Liu Y, Hashizume K, Chen Z, Samoto K, Ningaraj N, et al. (2001) Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol Res 23: 379-387.
48. Liu LB, Xue YX, Liu YH, Wang YB, (2008) Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin cytoskeleton. J Neurosci Res 86: 1153-1168.
49. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr, et al. (2000) Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 97: 8140-8145.
50. Walther T, Balschun D, Voigt JP, Fink H, Zuschratter W, et al. (1998) Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem 273: 11867-11873.
51. Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, et al. (1995) Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270: 13706-13710.
52. Costa R, Motta EM, Dutra RC, Manjavachi MN, Bento AF, et al. (2011) Anti-nociceptive effect of kinin B(1) and B(2) receptor antagonists on peripheral neuropathy induced by paclitaxel in mice. Br J Pharmacol.
53. Dutra R, Cola M, Leite D, Bento A, Claudino R, et al. (2011) Inhibitor of PI3Kgamma ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4(+) CD25(+) FoxP3(+) regulatory T cells. Br J Pharmacol 163: 358-374.
54. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
55. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T, (2010) Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 171: 852-858.